Individuals who reported a neutral level of satisfaction with their sense of belonging were approximately 3 times more likely to express an intent to leave, while those who were dissatisfied were 7 times more likely to do so, compared to individuals who were satisfied with their sense of belonging.
"Readers should not have to infer what was probably done; they should be told explicitly." This principle drives the comprehensive CONSORT 2025 update, with its 7 new checklist items aimed at improving clinical trial transparency.
Mavacamten's phase III trial for nonobstructive hypertrophic cardiomyopathy does not show significant improvement in functional capacity or symptoms, reflecting challenges in less severe populations. Bristol Myers Squibb plans to present full data at a future scientific meeting.
In a registry-based study of 79,550 patients, tenecteplase showed comparable short-term safety and effectiveness to alteplase for acute ischemic stroke, with no significant differences in functional outcomes or hemorrhagic events.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.